Eli Lilly Stock Outlook: Amgen's Obesity Drug Data and Market Share

Amgen's Maritide and Market Competition

• 💡 The key factor for Amgen's Maritide is the incidence of nausea and vomiting, as efficacy is less of a concern than side effects.
• ⚠️ Maritide is not expected until 2028 or 2029, by which time Eli Lilly and Novo Nordisk will have multiple obesity drugs on the market, potentially limiting Maritide's market share.
• 🚀 While Maritide's potential as a once-a-month or even quarterly injection is advanced, its late market entry could hinder its success.

Eli Lilly's Stock Valuation and Future

• 📈 Eli Lilly has seen significant stock appreciation, reaching a $1,100 price target, but further substantial short-term gains may be challenging.
• 💰 The stock's current valuation, trading at approximately 31 times next year's estimated earnings of $35 per share, might lead investors to take profits if favorable data emerges for competitors.
• 📊 Companies like Merck and Bristol Myers Squibb trade at much lower multiples (11-12 times earnings), despite having strong pipelines in other areas.

The Transformative Obesity Drug Category

• 🎯 The obesity drug market is projected to grow from $20 billion this year to $150 billion by 2030, representing a transformative drug class.
• 🩺 These drugs, including incretins and amylins, not only improve quality of life but also help prevent morbidity, mortality, and costs associated with chronic conditions.
• 💰 A recent analysis suggests that drugs like Zepbound, when combined with lifestyle management, can be cost-saving for the healthcare system, unlike other drug categories.
• ⚠️ While Merck and Bristol Myers are not expected to be significant players in the obesity market, Eli Lilly and Novo Nordisk are positioned to benefit from this expanding category.